We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 32.44 | 32.44 | 32.44 | 0.00 | 01:00:00 |
From Apr 2019 to Apr 2024
By Max Bernhard
Germany's Merck KGaA (MRK.XE) on Wednesday backed its guidance for the year and said that it also expects profitable growth in the years to come.
"For 2019, we continue to assume that the group will increase all its key figures: sales, EBITDA pre and EPS pre. We also have our sights firmly set on profitable growth for 2020 and beyond," Chief Executive Stefan Oschmann said at the pharmaceutical company's capital markets day.
Merck also said that by 2022, it targets additional annual sales of around 2 billion euros with new medicines. Its Mavenclad and Bavencio drugs are expected to contribute significantly to this, it added.
The company said it aims for maintained above-market growth in its life-science business and for its performance materials unit to resume growth as of 2020.
Write to Max Bernhard at max.bernhard@dowjones.com; @mxbernhard
(END) Dow Jones Newswires
September 11, 2019 02:02 ET (06:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
